Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential
14th Nov 2006, 18:25 GMT
Preliminary results from a phase 2 trial demonstrate that bevacizumab added on top of new-formulation paclitaxel and standard carboplatin is well tolerated and offers promising activity in patients with nonsquamous non?small-cell lung cancer. Medscape Medical News Allison Gandey
Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential related news:
- Lung cancer top killer among malignant tumors in Beijing — KeralaNext: China
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit — EurekAlert! - Medicine and Health
- NICE disapproves the use of cancer drug Tarceva — The Earth Times Online Newspaper
- Roswell signs for lung cancer registry — Latest news from Business First of Buffalo
- Lung Carcinogenesis Tracked By DNA Methylation Mapping In Exhaled Breath — ScienceDaily Headlines
- More Patients Asking for Lung Cancer Scans — RedOrbit News - Health
- Watchdog rules against new treatment for lung cancer — Guardian Unlimited UK Latest
- Vaccination With Embryonic Stem Cells Prevents Lung Cancer In Mice — Health News from Medical News Today
- Anti-cancer drug shows early promise in pulmonary hypertension — EurekAlert! - Breaking News
- Scientists Developing Lung Cancer Breath Test (HealthDay) —
Latest news from Medscape Headlines:
- New Treatment for Ischemic Stroke on the Horizon
- Type 1 and 2 T Helper Cell-mediated Colitis
- Radiation Therapy for Chronic Vesicular Hand Dermatitis
- November 14, 2006: In the News
- Alcoholic Liver Disease-Pathophysiological Aspects and Risk Factors
- Overweight in Celiac Disease: Prevalence, Clinical Characteristics, and Effect of a Gluten-Free Diet
- Bleeding-Edge Benefits
- End-Stage Renal Disease and Drug-Eluting Stents: One Small Step Forward?
- November 13, 2006: In the News
- Advanced NSCLC: Tailoring Treatment to the Patient